TENNESSEE ANTIGEN IN CANCER DIAGNOSIS

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 9326
Amount: $368,000.00
Phase: Phase II
Program: SBIR
Awards Year: 1988
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
Jcl Clinical Research Corp.
Rte 46,strawplains Pike, P O Box 6275, Knoxville, TN, 37914
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Thomas R Potter Jr
 () -
Business Contact
Phone: (615) 546-0654
Research Institution
N/A
Abstract
A NEW TUMOR-ASSOCIATED ANTIGEN, CALLED TENNESSEE ANTIGEN (TAG), HAS BEEN ISOLATED FORM 95 PERCENT OF 154 PRIMARY HUMAN GASTROINTESTINAL TUMORS. IN 208 PATIENTS WITH COLORECTAL CARCINOMA, 81 PERCENT SHOWED ELEVATED LEVELS OF TAG IN THEIR SERA. PHASE I STUDIES RESULTED IN THE PRODUCTION OF MONOCLONAL ANTIBODIES (MOAB'S) AND THE DEVELOPMENT OF AN ENZYME-LINKED IMMUNOASSAY (EIA) TO MEASURETAG IN SERUM. IN PHASE II IT IS PLANNED TO CONTINUE TO PRODUCE AND CHARACTERIZE MOAB'S USING WESTERN BLOTTING, IMMUNOFLUORESCENCE, AND IMMUNOHISTOCHEMICAL STAINING. THE SPECIFICITY, SENSITIVITY AND REPRODUCIBILITY OF EIA WILL BE STUDIED. A PROTOTYPE OF THE TAG-EIA KIT WILL BE DEVELOPED AND THE CLINICALLY UTILITY OF THE TAG-EIA WILL ALSO BE EVALUATED. THE OBJECTIVES OF THIS PROJECT ARE TWO-FOLD: (1) UTILIZATION OF MOAB'S TO TAG AS REAGENTS IN PATHOLOGICAL EXAMINATION OF CANCERS, AND (2) COMMERCIALIZATION OF THE TAG-EIA FOR DIAGNOSIS AND MANAGEMENT OF SOLID CANCERS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government